酷游ku娱乐入口-酷游ku游官网app-ku九州酷游app网址

G1G2-pcbanner-212.jpg G1G2-phbanner-280.jpg
BD and Collaboration

Suzhou Ribo Life Science Co., Ltd. (Ribo) is a company dedicated to discovering, developing and commercializing innovative  oligonucleotide therapeutics (mainly siRNA, also ASO and aptamer), and is the pioneer and leading player in  this sector in China.

Ribo has built a vertically integrated R&D platform including various aspects of proprietary technologies, facilities and a highly qualified professional team that have enabled the development of a significant pipeline of oligonucleotide therapeutics.

Cooperation opportunities
  • We cherish all opportunities of research and development cooperations in the broad field of oligonucleotide therapeutics, including license-out & license-in of pipeline products and technologies, collaboration on targeting of novel targets and development of novel technologies
Cooperation projects
2021

Ribo acquired the exclusive rights to develop, manufacture and commercialize anti-VEGF/Ang2 bispecific aptamer licensed from Aptitude Medical Systems Inc. in Greater China.

2017

Ribo acquired the exclusive rights to develop, manufacture and commercialize 3 antisense oligonucleotide therapeutics licensed from Ionis Pharmaceuticals Inc. in China.

2016

Ribo acquired the exclusive rights to develop, manufacture and commercialize BT-200 licensed from Band Therapeutics Inc. in Greater China.

2013

Ribo obtained the rights licensed from Life Technologies, Inc. (acquired by Thermo Fisher Scientific in 2014) to apply the liposome delivery technology for development of oligonucleotide therapeutics in China.

2012

Ribo entered into a strategic partnership with Quark Pharmaceuticals Inc. to fuel the development and commercialization of RNAi drugs in most of Asian countries.

Contact BD

Address of the Beijing (Daxing) branch: Floor 3, 3B-2 CR Life Sciences, Building 3, Courtyard 16, Baoshen South Street, Daxing District, Beijing
102600
BD@city-rockers.com
010-60277708